Category: Mergers and Acquisitions

September 10, 2021

Boehringer Ingelheim will use the same concept in a new research collaboration with San Francisco-based Twist Bioscience, harnessing its antibody libraries to discover therapeutic antibodies that work against a range of BI targets. Twist’s ability to manufacture DNA at scale […]

September 8, 2021

The deal with see Adaptimmune receive $150m upfront, another $150m over the next five years and then milestone payments potentially exceeding $3bn in aggregate sales, as well as royalties. Unlike other leaders in next-generation cell therapies, the partners will use […]

August 23, 2021

Biotechs targeting the “don’t eat me” signal cancer cells use to avoid the immune system are getting gobbled up. Pfizer is the latest company to buy its way into the space, splashing out $2.3 billion to acquire Trillium Therapeutics for […]

August 13, 2021

On Aug 12, 2021, Lykan Bioscience, a US-based contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, a US-based enterprise software platform company, announced a partnership that will combine Lykan’s purpose-built, multi-product cell therapy manufacturing facility located […]

July 28, 2021

Just two months after getting a swift approval for its closely watched KRAS lung cancer drug Lumakras, Amgen is not resting on its laurels and has penned a major new buyout deal to further boost its oncology pipeline. The biopharma […]

July 27, 2021

AZ’s buy into the programme comes a few weeks after Regeneron published findings in the journal Science suggesting that people with certain GPR75 mutations have 54% reduced risk of obesity, based on sequencing data from almost 650,000 people in the […]

July 13, 2021

Biogen is paying $125 million upfront to work on InnoCare’s orelabrutinib, an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi) that the pair hope can cut it in multiple sclerosis. Biogen, much in need of some new innovation in multiple […]

July 7, 2021

The EU approval comes after the merger has already been okayed by the US, Japan and a number of other countries around the world, and AZ says it is now hoping to completing the transaction by the end of this […]

July 1, 2021

Celularity Inc., a clinical-stage biotechnology company developing cell therapies and biomaterial products derived from the postpartum human placenta to treat cancer, infectious, and degenerative diseases, and Arthrex, Inc., a global leader in minimally invasive orthopedic technology, announced on July 1, […]

June 18, 2021

The two companies will collaborate on the development of targeted NK cell and macrophage cells derived from induced pluripotent stem cells (iPSC), cementing a relationship that has already seen Kite invest in Shoreline’s first-round financing, which raised $43 million in […]

June 9, 2021

The treatment, being developed by Merck in collaboration with Ridgeback Biotherapeutics, is currently being evaluated in a phase 3 clinical trial. The trial, know as the MOVe-OUT study, is evaluating molnupiravir in the treatment of non-hospitalised patients with laboratory-confirmed COVID-19 […]

June 3, 2021

Venture capitalists interested in biotech have been able to raise money with unprecedented ease over the past several years. Polaris Partners, 5AM Ventures, Third Rock Ventures, Versant and venBio are just some of the firms to have secured hundreds of […]